Citations (33)
Keep up to date with the latest research on this topic with citation updates for this article.
Articles from other publishers (33)
Nargess Arandi, Omid Reza Zekavat, Negin Shokrgozar, Amin Shahsavani, Hossein Golmoghaddam & Mehdi Kalani. (2023)
Altered frequency of
FOXP3
+
regulatory T cells is associated with development of inhibitors in patients with severe hemophilia A
. International Journal of Laboratory Hematology 45:6, pages 953-960.
Crossref
Crossref
Ali Rajabi Zangi, Ala Amiri, Pouya Pazooki, Fatemeh Soltanmohammadi, Hamed Hamishehkar & Yousef Javadzadeh. (2023) Non-viral and viral delivery systems for hemophilia A therapy: recent development and prospects. Annals of Hematology.
Crossref
Crossref
Juan A. De Pablo-Moreno, Andrea Miguel-Batuecas, E. Carlos Rodríguez-Merchán & Antonio Liras. (2023) Treatment of congenital coagulopathies, from biologic to biotechnological drugs: The relevance of gene editing (CRISPR/Cas). Thrombosis Research 231, pages 99-111.
Crossref
Crossref
Liping Luo, Qiaoyun Zheng, Zhenyu Chen, Meijuan Huang, Lin Fu, Jianda Hu, Qizhen Shi & Yingyu Chen. (2022) Hemophilia a patients with inhibitors: Mechanistic insights and novel therapeutic implications. Frontiers in Immunology 13.
Crossref
Crossref
David W. Scott. (2022) Until programmed death do us tolerant. Journal of Clinical Investigation 132:22.
Crossref
Crossref
Janine Becker-Gotot, Mirjam Meissner, Vadim Kotov, Blanca Jurado-Mestre, Andrea Maione, Andreas Pannek, Thilo Albert, Chrystel Flores, Frank A. Schildberg, Paul A. Gleeson, Birgit M. Reipert, Johannes Oldenburg & Christian Kurts. (2022) Immune tolerance against infused FVIII in hemophilia A is mediated by PD-L1+ Tregs. Journal of Clinical Investigation 132:22.
Crossref
Crossref
Wei Liu, Cuicui Lyu, Wentian Wang, Feng Xue, Lingling Chen, Huiyuan Li, Ying Chi, Yueshen Ma, Runhui Wu, Yunhai Fang, Lei Zhang & Renchi Yang. (2022) Risk factors for inhibitors in hemophilia A based on RNA‐seq and DNA methylation. Research and Practice in Thrombosis and Haemostasis 6:6, pages e12794.
Crossref
Crossref
Jorge Vela-Ojeda, Jaime Garcia-Chavez, Abraham Majluf-Cruz, Elba Reyes-Maldonado, Miriam A. Garcia-Ruiz Esparza & Laura A. Montiel-Cervantes. (2021) Important decrease in invariant natural killer T, CD4+ regulatory T cells, CD8+ regulatory T cells, gamma–delta T cells, and CD4+ T lymphocytes in HIV-negative patients with hemophilia. Blood Coagulation & Fibrinolysis 32:1, pages 8-15.
Crossref
Crossref
Richard Y. Fu, Alex C. Chen, Meghan J. Lyle, Chun-Yu Chen, Chao Lien Liu & Carol H. Miao. (2020) CD4+ T cells engineered with FVIII-CAR and murine Foxp3 suppress anti-factor VIII immune responses in hemophilia a mice. Cellular Immunology 358, pages 104216.
Crossref
Crossref
Roland W. Herzog, Veronica Kuteyeva, Rania Saboungi, Cox Terhorst & Moanaro Biswas. (2019) Reprogrammed CD4+ T Cells That Express FoxP3+ Control Inhibitory Antibody Formation in Hemophilia A Mice. Frontiers in Immunology 10.
Crossref
Crossref
Kyuri Lee, Bora Jang, You-ri Lee, Eun-young Suh, Ji-seon Yoo, Mi-jin Lee, Joo-young Lee & Hyukjin Lee. (2018) The cutting-edge technologies of siRNA delivery and their application in clinical trials. Archives of Pharmacal Research 41:9, pages 867-874.
Crossref
Crossref
S.J. Schep, R.E.G. Schutgens, K. Fischer & M.L. Boes. (2018) Review of immune tolerance induction in hemophilia A. Blood Reviews 32:4, pages 326-338.
Crossref
Crossref
Moanaro Biswas, Sandeep R. P. Kumar, Cox Terhorst & Roland W. Herzog. (2018) Gene Therapy With Regulatory T Cells: A Beneficial Alliance. Frontiers in Immunology 9.
Crossref
Crossref
Guglielmo Mariani, Barbara A. Konkle & Craig M. Kessler. 2018. Hematology. Hematology
2023
2033.e5
.
Alexandra Sherman, Moanaro Biswas & Roland W. Herzog. (2017) Innovative Approaches for Immune Tolerance to Factor VIII in the Treatment of Hemophilia A. Frontiers in Immunology 8.
Crossref
Crossref
Y. Chen, X. Luo, J.A. Schroeder, J. Chen, C.K. Baumgartner, J. Hu & Q. Shi. (2017) Immune tolerance induced by platelet‐targeted factor VIII gene therapy in hemophilia A mice is CD4 T cell mediated. Journal of Thrombosis and Haemostasis 15:10, pages 1994-2004.
Crossref
Crossref
Xiaomei Wang, Cox Terhorst & Roland W. Herzog. (2016) In vivo induction of regulatory T cells for immune tolerance in hemophilia. Cellular Immunology 301, pages 18-29.
Crossref
Crossref
A. Fogdell-Hahn. (2015) Antidrug Antibodies: B Cell Immunity Against Therapy. Scandinavian Journal of Immunology 82:3, pages 184-190.
Crossref
Crossref
Alexandra Sherman, Jin Su, Shina Lin, Xiaomei Wang, Roland W. Herzog & Henry Daniell. (2014) Suppression of inhibitor formation against FVIII in a murine model of hemophilia A by oral delivery of antigens bioencapsulated in plant cells. Blood 124:10, pages 1659-1668.
Crossref
Crossref
J. Oldenburg, S. K. Austin & C. M. Kessler. (2014) ITI choice for the optimal management of inhibitor patients - from a clinical and pharmacoeconomic perspective. Haemophilia 20, pages 17-26.
Crossref
Crossref
C.L. Liu, P. Ye, J. Lin, D. Djukovic & C.H. Miao. (2014) Long‐term tolerance to factor VIII is achieved by administration of interleukin‐2/interleukin‐2 monoclonal antibody complexes and low dosages of factor VIII. Journal of Thrombosis and Haemostasis 12:6, pages 921-931.
Crossref
Crossref
D. W. Scott. (2014) Inhibitors - cellular aspects and novel approaches for tolerance. Haemophilia 20, pages 80-86.
Crossref
Crossref
Debalina Sarkar, Moanaro Biswas, Gongxian Liao, Howard R Seay, George Q Perrin, David M Markusic, Brad E Hoffman, Todd M Brusko, Cox Terhorst & Roland W Herzog. (2014) Ex vivo expanded autologous polyclonal regulatory T cells suppress inhibitor formation in hemophilia. Molecular Therapy - Methods & Clinical Development 1, pages 14030.
Crossref
Crossref
L. A. Valentino, G. Allen, J. C. Gill, A. Hurlet, B. A. Konkle, C. A. Leissinger, L. Luchtman-Jones, J. Powell, M. Reding & K. Stine. (2013) Case studies in the management of refractory bleeding in patients with haemophilia A and inhibitors. Haemophilia 19:3, pages e151-e166.
Crossref
Crossref
Char Witmer & Guy Young. (2012) Factor VIII inhibitors in hemophilia A: rationale and latest evidence. Therapeutic Advances in Hematology 4:1, pages 59-72.
Crossref
Crossref
Kathleen P. Pratt. (2012) Inhibitory antibodies in hemophilia A. Current Opinion in Hematology 19:5, pages 399-405.
Crossref
Crossref
Toshio TanakaMasashi NarazakiTadamitsu Kishimoto. (2012) Therapeutic Targeting of the Interleukin-6 Receptor. Annual Review of Pharmacology and Toxicology 52:1, pages 199-219.
Crossref
Crossref
David W. Scott & Jay N. Lozier. (2012) Gene therapy for haemophilia: prospects and challenges to prevent or reverse inhibitor formation. British Journal of Haematology 156:3, pages 295-302.
Crossref
Crossref
Toshio Tanaka & Tadamitsu Kishimoto. (2012) Immunotherapeutic implication of IL-6 blockade. Immunotherapy 4:1, pages 87-105.
Crossref
Crossref
Toshio Tanaka, Keisuke Hagihara, Yoshihito Shima, Masashi Narazaki, Atsushi Ogata & Atsushi Kumanogoh. (2011) Tocilizumab, a humanized anti-interleukin-6 receptor antibody, for the treatment of autoimmune disorders. Drug Development Research 72:8, pages 717-732.
Crossref
Crossref
C.H. MIAO. (2011) Tilt balance towards regulation: evolving new strategy for treatment of hemophilia inhibitors. Journal of Thrombosis and Haemostasis 9:8, pages 1521-1523.
Crossref
Crossref
Chao-Lien Liu, Peiqing Ye, Benjamin C Yen & Carol H Miao. (2011) In Vivo Expansion of Regulatory T cells With IL-2/IL-2 mAb Complexes Prevents Anti-factor VIII Immune Responses in Hemophilia A Mice Treated With Factor VIII Plasmid-mediated Gene Therapy. Molecular Therapy 19:8, pages 1511-1520.
Crossref
Crossref
B. PAUTARD, R. D’OIRON, V. LI THIAO TE, R. LAVEND’HOMME, J.‐M. SAINT‐REMY, K. PEERLINCK & M. JACQUEMIN. (2011) Successful immune tolerance induction by FVIII in hemophilia A patients with inhibitor may occur without deletion of FVIII‐specific T cells. Journal of Thrombosis and Haemostasis 9:6, pages 1163-1170.
Crossref
Crossref